Swapped for MEMP because they have longer hedges and I'm afraid the price might not turn soon enough for BBEP. Good luck and God Bless to you longs. This has been a very large loss of capital for me. And to think I was deciding between PSX and MLP"s with a hedge...tragic mistake!
I had talked to BBEP about this and the IR person, who I believe is no longer there, mentioned a potential tax consequence for the unit holders. They were planning to offer senior secured notes to the unsecured owners at something like 50%. Not sure if their senior secured was trading 50% higher in the market.
I swapped the rest of my remaining BBEP loser stock today for MEMP. I'm hoping and praying for a turn before the money runs out and MEMP has longer hedges. I'm sure BBEP will be acquired now! Someone needs to wake the Saudis, or a few well targeted Russian...
"if" true, it's possible someone at JNJ tipped someone off, but ACHN's execs were not aware and in fact there were some insider sales, so there's no way they were made aware or they would not have been able to sell. They need to provide an update and verify this either way.
It's been a tough year+ for everyone. I came into 2015 with 50% cash, expected a difficult year, bought some oil stocks when the price first touched $40. One stock almost doubled the other (an MLP) just kept going lower and I kept adding and adding...It's a disaster.
Very interesting pipeline including 3 drugs with large market potential and one approved drug that's not being marketed properly. At the current valuation or even 4-5x the current valuation, it's a steal. Shareholders are not happy with management, the stock is heavily shorted. Some smart pharma or biotech is going to buy them and make a killing IMO. The longer you wait, the more evidence that builds for the pipeline, the more you will pay later.
sounds reasonable. I think we would know right away if it's significantly better or worse than expected and so I'm speculating that ACHN has not been made aware of the results yet and that likely means the trial has either not finished, or the data have not collected and analyzed yet.
For now, ACHN is stuck trading with the market, IBB and XBI and lately that's not a good thing. We all better pray and vote that Hillary of the socialist are not made the next president. The current socialist President has been in long enough.
I already told you I called the company, talked to a "senior person" and she said expected JNJ to release at a major conference in April (I thought early April) unless there was material info sooner, then it would need to be released right away. That may have changed, she did not respond to my last email asking for the analyst report (downgrade) and name/date of the conference in April. You folks need to be patient and wait for the data. Speculating every day is a waste of time.
ARNA does not have the funds to develop this and needs the influence of big pharma to get it through the process. Hoping for an acquirer, or partner leading to acquirer after approval and sales success...We just need one of the 3 to work!
all of that drop can be explained by XBI/industry/Hillary/Shkrelli etc. Hoping they continue to buy after the fool's testimony or appearance today.
the problem is, with only 20 people per arm it's either 100, 95, 90, 85...Hoping for the best, but we don't even know if they have the treatment combo's and timing of each drug and amounts of each drug optimized at this point. They may need to tweak some things to get 95 or 100%.
the reason for failure is lack of selectivity. I talked to an industry research pro from a large pharma about this. He said they would look for better than 10:1. CA said the ratio for ARNA's product is something like 10,000:1. It could certainly fail for many other reasons, but the most common reason is not a problem.
machine was broken all day? Maybe shorts are letting it float up so they can short more.
1) it will never pass 2) if they were going to do something like this they should have tried a tax on gasoline, but that would have been less politically correct since it's a tax that would hurt the poor more than the rich.
Another brain dead, business negative proposal from out the soon to be unemployed fool in the Whitehouse. Don't let the door hit you in the #$%$ Obama!
I prefer an acquisition, but would settle for a partnership with a top tier firm. No more Eisai partnerships, they are terrible!!!
Gilead's John Milligan--soon to be CEO--cited three key areas of interest: oncology, inflammatory diseases and liver diseases. I believe ARNA addresses at least 1 or 2 of these, but not Oncology. Inflamation, yes!. Not sure we can count liver. I don't buy the NASH info, I think's it's just related to weight loss.